Medico Remedies Ltd. (IN:MEDICO)
:MEDICO
Want to see IN:MEDICO full AI Analyst Report?
Top Page
Medico Remedies Ltd.
(MEDICO)
Select Model
Select Model
Rating:64Neutral
Price Target:
₹45.00
▼(-10.29% Downside)
Action:ReiteratedDate:04/02/26
The score is primarily supported by strong underlying financial performance (growth and improving profitability with reasonable leverage). This is materially offset by weak technicals (below key moving averages with negative MACD) and a relatively high P/E with no dividend yield support.
Positive Factors
Revenue Growth & Profitability
Consistent revenue expansion and improving net margins indicate structural demand for the company’s products and growing profitability. Over 2-6 months this supports sustained cash generation, reinvestment capacity and resilience versus peers, underpinning long-term business stability.
Negative Factors
Volatile EBIT Margin
Less stable EBIT margins point to variability in operating efficiency or cost structure, which weakens earnings predictability. Over months this can amplify earnings volatility, complicate planning for capex or R&D, and reduce visibility into sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Profitability
Consistent revenue expansion and improving net margins indicate structural demand for the company’s products and growing profitability. Over 2-6 months this supports sustained cash generation, reinvestment capacity and resilience versus peers, underpinning long-term business stability.
Read all positive factors
Medico Remedies Ltd. (MEDICO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹3.33B
Dividend YieldN/A
Average Volume (3M)12.74K
Price to Earnings (P/E)36.5
Beta (1Y)0.22
Revenue Growth26.44%
EPS Growth31.04%
CountryIN
Employees193
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.35
Shares Outstanding82,984,000
10 Day Avg. Volume20,955
30 Day Avg. Volume12,740
Financial Highlights & Ratios
PEG Ratio1.99
Price to Book (P/B)7.06
Price to Sales (P/S)2.92
P/FCF Ratio258.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Medico Remedies Ltd. Business Overview & Revenue Model
Company Description
Medico Remedies Limited manufactures and sells allopathic pharmaceutical preparations in India. The company offers antibiotics and anti-infective drugs; beta-lactams, and penicillins and cephalosporins; antifungals; vitamins and supplements; cardi...
How the Company Makes Money
null...
Medico Remedies Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.72B | 1.51B | 1.45B | 1.40B | 1.21B | 1.22B |
| Gross Profit | 478.71M | 426.11M | 175.25M | 355.66M | 176.65M | 234.09M |
| EBITDA | 191.22M | 150.03M | 177.36M | 135.66M | 93.34M | 62.59M |
| Net Income | 113.47M | 100.93M | 82.91M | 72.42M | 48.12M | 25.90M |
Balance Sheet | ||||||
| Total Assets | 1.37B | 1.20B | 961.95M | 874.48M | 761.90M | 756.21M |
| Cash, Cash Equivalents and Short-Term Investments | 17.64M | 25.45M | 15.46M | 21.95M | 23.40M | 38.86M |
| Total Debt | 125.27M | 147.00M | 80.50M | 97.62M | 125.97M | 150.53M |
| Total Liabilities | 704.99M | 573.30M | 438.24M | 436.05M | 388.70M | 431.63M |
| Stockholders Equity | 668.58M | 624.69M | 523.71M | 438.43M | 373.20M | 324.58M |
Cash Flow | ||||||
| Free Cash Flow | -5.86M | 17.07M | 2.04M | 15.75M | -11.50M | 4.72M |
| Operating Cash Flow | 6.43M | 48.92M | 26.83M | 81.67M | 17.10M | 26.08M |
| Investing Cash Flow | -12.01M | -34.60M | -26.77M | -66.03M | -17.56M | -169.60M |
| Financing Cash Flow | -2.70M | -5.20M | -4.90M | -18.17M | -57.71M | 182.80M |
Medico Remedies Ltd. Technical Analysis
Neutral
50.16
Price Trends
42.22
Negative
46.30
Negative
45.18
Negative
Market Momentum
-0.55
Negative
56.44
Neutral
73.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDICO, the sentiment is Neutral. The current price of 50.16 is above the 20-day moving average (MA) of 37.67, above the 50-day MA of 42.22, and above the 200-day MA of 45.18, indicating a neutral trend. The MACD of -0.55 indicates Negative momentum. The RSI at 56.44 is Neutral, neither overbought nor oversold. The STOCH value of 73.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:MEDICO.
Medico Remedies Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹3.20B | 48.53 | ― | ― | -0.51% | 124.85% | |
64 Neutral | ₹3.33B | 36.55 | ― | ― | 26.44% | 31.04% | |
63 Neutral | ₹4.54B | 19.99 | ― | ― | -2.65% | -54.56% | |
55 Neutral | ₹3.37B | 56.53 | ― | 0.26% | -7.50% | 6.39% | |
52 Neutral | ₹4.44B | -13.45 | ― | ― | 91.43% | 18.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ₹4.11B | 6.87 | ― | 0.66% | -10.36% | -76.23% |
* Healthcare Sector Average
IN:MEDICO
Medico Remedies Ltd.
40.08
-14.96
-27.18%
IN:ALBERTDAVD
Albert David Ltd
720.00
-106.12
-12.85%
IN:BAFNAPH
Bafna Pharmaceuticals Limited
135.30
54.70
67.87%
IN:MEDICAMEQ
Medicamen Biotech Limited
248.15
-183.80
-42.55%
IN:VALIANTLAB
Valiant Laboratories Ltd.
81.70
-10.98
-11.85%
IN:ZIMLAB
Zim Laboratories Ltd.
84.70
-2.87
-3.28%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.